PIPAC for peritoneal cancer: The Epworth experience.

Abstract

Peritoneal carcinomatosis has a relentlessly aggressive clinical course. Pressurized Intraperitoneal Aerosol Chemotherapy entails accessing the abdominal cavity using standard laparoscopic techniques and delivering aerosolized chemotherapeutic agents via a high pressure micro injection pump. This novel therapeutic approach can repeatedly deliver a localised therapy with enhanced tolerability and minimal morbidity to improve local disease control. Early results suggest PIPAC is feasible, safe, and well tolerated. Patients having repeated PIPAC procedures had increased survival. Limitations include the small sample size and heterogeneity of the patient group.